Agios Pharmaceuticals Insider Trades
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 39 · $4.78M
- Shares bought / sold
- 0 / 154.57K
- Net activity
- Net selling $4.8 million
Agios Pharmaceuticals insider activity
Over the last 12 months, Agios Pharmaceuticals insiders reported 87 transactions on SEC Form 4: 0 open-market purchases and 39 sales. Insiders bought $0 and sold $4.8 million worth of stock, for net insider selling of $4.8 million. The largest seller was Gheuens Sarah, with $1.7 million in reported sales.
The most recent filing shows Gheuens Sarah (Chief Medical Officer) reporting a transaction in 7,866 shares at $25.01 on Oct 26, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put AGIO's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
AGIO insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 26, 2026 | Gheuens SarahChief Medical Officer | Sale | 7,866 | $296.47K | Form 4 |
| Oct 26, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 7,866 | $196.73K | Form 4 |
| Oct 22, 2026 | Gheuens SarahChief Medical Officer | Sale | 500 | $18.76K | Form 4 |
| Oct 22, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 500 | $12.51K | Form 4 |
| Oct 21, 2026 | Gheuens SarahChief Medical Officer | Sale | 1,489 | $55.88K | Form 4 |
| Oct 21, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 1,489 | $37.24K | Form 4 |
| Aug 4, 2026 | Gheuens SarahChief Medical Officer | Sale | 30,000 | $914.40K | Form 4 |
| Jul 8, 2026 | Backstrom Jay T.Director | Award | 1,447 | — | Form 4 |
| Jul 1, 2026 | Gheuens SarahChief Medical Officer | Sale | 4,007 | $150.50K | Form 4 |
| Jul 1, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 8,375 | — | Form 4 |
| Jun 18, 2026 | Smith CynthiaDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | Scadden DavidDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | FOUSE JACQUALYN ADirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | Owen Adams CatherineDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | Ho MaykinDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | Foster-Cheek Kaye IDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | CAPELLO JEFFREY DDirector | Option exercise | 2,816 | — | Form 4 |
| Jun 18, 2026 | Ballal Rahul D.Director | Option exercise | 2,816 | — | Form 4 |
| Jun 13, 2026 | CAPELLO JEFFREY DDirector | Option exercise | 1,976 | — | Form 4 |
| Jun 13, 2026 | Owen Adams CatherineDirector | Option exercise | 1,976 | — | Form 4 |
| Apr 2, 2026 | Goff BrianChief Executive Officer | Sale | 6,596 | $228.95K | Form 4 |
| Apr 2, 2026 | Goff BrianChief Executive Officer | Option exercise | 13,500 | — | Form 4 |
| Apr 2, 2026 | Goff BrianChief Executive Officer | Sale | 12,472 | $432.90K | Form 4 |
| Apr 2, 2026 | Goff BrianChief Executive Officer | Option exercise | 25,528 | — | Form 4 |
| Apr 2, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy | Sale | 2,959 | $102.71K | Form 4 |
| Apr 2, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy | Option exercise | 8,100 | — | Form 4 |
| Apr 2, 2026 | Milanova TsvetaChief Commercial Officer | Sale | 3,262 | $113.22K | Form 4 |
| Apr 2, 2026 | Milanova TsvetaChief Commercial Officer | Option exercise | 8,500 | — | Form 4 |
| Apr 2, 2026 | Jones CeciliaChief Financial Officer | Sale | 3,141 | $109.02K | Form 4 |
| Apr 2, 2026 | Jones CeciliaChief Financial Officer | Option exercise | 8,500 | — | Form 4 |
| Apr 2, 2026 | Gheuens SarahChief Medical Officer | Sale | 2,940 | $102.05K | Form 4 |
| Apr 2, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 8,500 | — | Form 4 |
| Apr 2, 2026 | Burns James WilliamChief Legal Officer | Sale | 3,280 | $113.85K | Form 4 |
| Apr 2, 2026 | Burns James WilliamChief Legal Officer | Option exercise | 8,500 | — | Form 4 |
| Mar 5, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy | Sale | 2,959 | $82.26K | Form 4 |
| Mar 5, 2026 | Viswanadhan KrishnanChief Corp Dev & Strategy | Option exercise | 8,100 | — | Form 4 |
| Mar 3, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Sale | 5,272 | $152.26K | Form 4 |
| Mar 2, 2026 | Milanova TsvetaChief Commercial Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Milanova TsvetaChief Commercial Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Milanova TsvetaChief Commercial Officer | Sale | 1,681 | $48.68K | Form 4 |
| Mar 2, 2026 | Milanova TsvetaChief Commercial Officer | Option exercise | 5,666 | — | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Sale | 798 | $23.11K | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Option exercise | 2,695 | — | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Sale | 727 | $21.05K | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Option exercise | 2,450 | — | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Sale | 698 | $20.21K | Form 4 |
| Mar 2, 2026 | Washburn Theodore James Jr.Principal Accounting Officer | Option exercise | 2,350 | — | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Sale | 1,573 | $45.55K | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Option exercise | 5,303 | — | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Sale | 1,681 | $48.68K | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Option exercise | 5,666 | — | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Sale | 594 | $17.20K | Form 4 |
| Mar 2, 2026 | Jones CeciliaChief Financial Officer | Option exercise | 2,000 | — | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Sale | 1,681 | $48.68K | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 5,666 | — | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Gheuens SarahChief Medical Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Sale | 1,163 | $33.68K | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Option exercise | 3,920 | — | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Sale | 1,681 | $48.68K | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Option exercise | 5,666 | — | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Sale | 1,187 | $34.38K | Form 4 |
| Mar 2, 2026 | Burns James WilliamChief Legal Officer | Option exercise | 4,000 | — | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Sale | 5,918 | $171.39K | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Option exercise | 13,000 | — | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Sale | 8,267 | $239.41K | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Option exercise | 18,000 | — | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Sale | 3,870 | $112.08K | Form 4 |
| Mar 2, 2026 | Goff BrianChief Executive Officer | Option exercise | 8,500 | — | Form 4 |
| Jan 5, 2026 | Milanova TsvetaChief Commercial Officer | Sale | 2,872 | $77.60K | Form 4 |
| Jan 5, 2026 | Milanova TsvetaChief Commercial Officer | Option exercise | 8,475 | — | Form 4 |
| Dec 30, 2025 | Gheuens SarahChief Medical Officer | Sale | 2,932 | $79.43K | Form 4 |
| Dec 30, 2025 | Gheuens SarahChief Medical Officer | Option exercise | 6,000 | — | Form 4 |
| Dec 30, 2025 | Goff BrianChief Executive Officer | Sale | 6,230 | $168.77K | Form 4 |
| Dec 30, 2025 | Goff BrianChief Executive Officer | Option exercise | 12,750 | — | Form 4 |
| Dec 30, 2025 | Goff BrianChief Executive Officer | Sale | 12,473 | $337.89K | Form 4 |
| Dec 30, 2025 | Goff BrianChief Executive Officer | Option exercise | 25,528 | — | Form 4 |
| Dec 30, 2025 | Burns James WilliamChief Legal Officer | Sale | 2,932 | $79.43K | Form 4 |
| Dec 30, 2025 | Burns James WilliamChief Legal Officer | Option exercise | 6,000 | — | Form 4 |
| Dec 30, 2025 | Milanova TsvetaChief Commercial Officer | Sale | 2,932 | $79.43K | Form 4 |
| Dec 30, 2025 | Milanova TsvetaChief Commercial Officer | Option exercise | 6,000 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4